1
Clinical Trials associated with ZYG24004A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 1b Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Different Concentrations of ZYG24004 in Participants With Tinea Pedis Caused by Dermatophytes
This is a multicenter, randomized, double-blind, placebo-controlled Phase 1b study in adult participants with tinea pedis caused by dermatophytes. The study will evaluate the safety, local tolerability, and pharmacokinetic profile of two concentrations of ZYG24004 (1% and 3%) after topical administration once or twice (once weekly for two consecutive weeks), and will explore preliminary efficacy.
Start Date21 Jul 2026 |
Sponsor / Collaborator- |
100 Clinical Results associated with ZYG24004
100 Translational Medicine associated with ZYG24004
100 Patents (Medical) associated with ZYG24004
100 Deals associated with ZYG24004